<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.ukri.org/api"><gtr:projectComposition><gtr:collaborations/><gtr:leadResearchOrganisation url="http://gtr.ukri.org:80/organisation/B8411B73-E4F0-406D-AEC1-A5963E8D7BA4"><gtr:id>B8411B73-E4F0-406D-AEC1-A5963E8D7BA4</gtr:id><gtr:name>Nanommune Biotech Ltd.</gtr:name><gtr:address><gtr:line1>1 Barn Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 9PN</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:typeInd>P</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.ukri.org:80/organisation/B8411B73-E4F0-406D-AEC1-A5963E8D7BA4" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:type="gtr:organisationParticipantRole"><gtr:id>B8411B73-E4F0-406D-AEC1-A5963E8D7BA4</gtr:id><gtr:name>Nanommune Biotech Ltd.</gtr:name><gtr:address><gtr:line1>1 Barn Road</gtr:line1><gtr:city>Cambridge</gtr:city><gtr:postCode>CB2 9PN</gtr:postCode><gtr:region>East of England</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>PARTICIPANT</gtr:name></gtr:role><gtr:role><gtr:name>LEAD_PARTICIPANT</gtr:name></gtr:role></gtr:roles><gtr:offerGrant>5000.0</gtr:offerGrant><gtr:projectCost>5000.0</gtr:projectCost></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.ukri.org:80/person/6BAA32D3-0592-4662-8707-B8FF49287B99"><gtr:id>6BAA32D3-0592-4662-8707-B8FF49287B99</gtr:id><gtr:firstName>Unknown</gtr:firstName><gtr:otherNames>Unknown</gtr:otherNames><gtr:surname>Unknown</gtr:surname><gtr:roles><gtr:role><gtr:name>PROJECT_MANAGER</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.ukri.org:80/projects?ref=751995"><gtr:id>F72668F5-C319-4BBE-84B9-A8248EB62B1F</gtr:id><gtr:title>Nanommune</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Vouchers</gtr:grantCategory><gtr:grantReference>751995</gtr:grantReference><gtr:abstractText>Based in Cambridge, UK, Nanommune Biotech has a
core focus on the discovery and development of nanoscale combinatorial cancer immunotherapies.
Based on the unique properties of quantum-dot nanoparticles and immunostimulatory monoclonal
antibodies, Nanommune Biotech aims to develop artificial costimulatory cells that can trigger a highly
effective anti-tumour immune response as a result of a multi-layered co-stimulation of T-cells in cancer
patients. The voucher will be used in IP advisers</gtr:abstractText><gtr:fund><gtr:end>2015-07-31</gtr:end><gtr:funder url="http://gtr.ukri.org:80/organisation/E18E2F0F-AC7D-4E02-9559-669F7C8FEC74"><gtr:id>E18E2F0F-AC7D-4E02-9559-669F7C8FEC74</gtr:id><gtr:name>Innovate UK</gtr:name></gtr:funder><gtr:start>2015-02-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>5000</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs/><gtr:disseminationOutputs/><gtr:exploitationOutputs/><gtr:furtherFundingOutputs/><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs/><gtr:productOutputs/><gtr:researchDatabaseAndModelOutputs/><gtr:researchMaterialOutputs/><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications/><gtr:identifiers><gtr:identifier type="RCUK">751995</gtr:identifier></gtr:identifiers><gtr:healthCategories/><gtr:researchActivities/><gtr:researchSubjects/><gtr:researchTopics><gtr:researchTopic><gtr:id>D05BC2E0-0345-4A3F-8C3F-775BC42A0819</gtr:id><gtr:text>Unclassified</gtr:text></gtr:researchTopic></gtr:researchTopics><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>